AAN 2021: Daily Atogepant Safe and Well Tolerated for Long-Term Prevention of Migraine
The 1-year follow-up demonstrated good safety and tolerability, including hepatic safety
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.